Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
Am J Respir Crit Care Med
.
2021 Jan 1;203(1):139-140.
doi: 10.1164/rccm.202007-2924LE.
Authors
Mathieu Blot
1
2
,
Abderrahmane Bourredjem
3
,
Christine Binquet
2
3
,
Lionel Piroth
1
3
;
LYMPHONIE Study Group
Collaborators
LYMPHONIE Study Group
:
Mathieu Blot
,
Abderrahmane Bourredjem
,
Christine Binquet
,
Lionel Piroth
,
Jean-Pierre Quenot
,
Pierre-Emmanuel Charles
,
François Aptel
,
Sébastien Prin
,
Pascal Andreu
,
Marie Labruyère
,
Auguste Dargent
,
Maxime Nguyen
,
Belaid Bouhemad
,
Marjolaine Georges
,
Philippe Bonniaud
,
Guillaume Beltramo
,
Marielle Buisson
,
Bernard Bonnotte
,
Philip Bielefeld
,
Jeremy Barben
,
Alain Putot
,
Serge Monier
,
Audrey Large
,
Suzanne Mouries-Martin
,
Hervé Devilliers
,
Pascal Chavanet
,
Alexandre Guilhem
Affiliations
1
Infectious Diseases Department University Hospital Dijon, France.
2
LNC INSERM UMR1231 Dijon, France and.
3
INSERM CIC1432 Clinical Epidemiology unit Dijon, France.
PMID:
32955921
PMCID:
PMC7781133
DOI:
10.1164/rccm.202007-2924LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19*
Humans
Interleukin-6*
SARS-CoV-2
Severity of Illness Index
Substances
Antibodies, Monoclonal, Humanized
Interleukin-6